Grifols, S.A.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jose Ignacio Abia Buenache
- Full Time Employees
- 23,833
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Avinguda de la Generalitat, 152 Barcelona Spain 08174
- IPO Date
- Jun 2, 2011
- CIK
- 0001438569
- Website
- grifols.com
- Similar Companies
- Business
- Grifols, S.A. (GRFS) is a global healthcare company and leading producer of plasma-derived medicines that develops, manufactures and distributes biological therapies, transfusion medicine solutions, clinical diagnostics and bio-supplies for life-science research. The company offers a comprehensive portfolio of plasma-derived products including immunoglobulins for primary and secondary immunodeficiencies and neurological disorders; albumin for intensive care and liver disease patients; Factor VIII and other coagulation factors for hemophilia A and bleeding disorders; Alpha-1 antitrypsin for genetic emphysema and chronic obstructive pulmonary disease; antithrombin for hereditary deficiencies; and specific hyperimmune immunoglobulins for post-exposure prophylaxis against rabies, tetanus and other diseases; alongside diagnostic technologies, reagents and instruments for blood typing, compatibility testing and transfusion safety; intravenous solutions, clinical nutrition products and medical devices for hospitals; and biological materials for pharmaceutical manufacturing and clinical trials. Grifols operates over 400 plasma collection centers worldwide, 15 industrial facilities across seven countries including a flagship plasma fractionation site in Clayton, North Carolina, and maintains a direct presence in more than 30 countries while serving over 110 markets, with a workforce exceeding 23,800 employees. Founded in 1909 in Barcelona as a clinical analysis laboratory and headquartered in Sant Cugat del Vallès, Barcelona, Spain, the company focuses on therapeutic areas such as immunology, infectious diseases, pulmonology and critical care. Among its latest major developments, Grifols invests EUR 160 million in a new manufacturing facility in Lliçà de Vall, Barcelona, set to double European plasma fractionation capacity by 2030 and create over 400 jobs; reaffirms 2025 guidance following strong 2024 results with revenue growth and reduced leverage to 4.5x; advances launches of Fibrinogen in Europe by Q4 2025 and the U.S. by H1 2026 post-FDA approval; strengthens partnerships including strategic alliances with Haier Group and Shanghai RAAS in China, Egyptian government for plasma self-sufficiency by 2026, and Canadian Blood Services; and terminated takeover discussions with Brookfield and the Grifols family in late 2024 while enhancing governance with independent directors.
Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript
Aldeyra Therapeutics (NASDAQ:ALDX) and Grifols (NASDAQ:GRFS) Head to Head Comparison
Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates
Grifols approves IPO of its US biopharma business
Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's Disease
Health Coalition demands disclosures & end to Grifols' for-profit blood plasma contract following reports of deaths, harm, non-compliance
Media Advisory: Press Conference Regarding Tragic Deaths After Plasma Harvesting at Grifols' Sites
Grifols: I'm Very Happy To Add In 2026
Diversify Wealth Management LLC Takes Position in Grifols, S.A. $GRFS
Grifols, S.A. (GIKLY) Q4 2025 Earnings Call Transcript
Grifols doubles net profit in 2025, driven by revenues
Grifols (GRFS) Expected to Announce Quarterly Earnings on Wednesday
Brandes Investment Partners, LP's Strategic Moves: Progressive Corp Leads with 1.04% Portfolio Impact
Grifols, S.A. (NASDAQ:GRFS) Given Average Recommendation of “Hold” by Brokerages
Grifols (NASDAQ:GRFS) Shares Pass Above 200 Day Moving Average – Should You Sell?
Grifols, S.A. (NASDAQ:GRFS) Given Consensus Recommendation of “Hold” by Analysts
Grifols: Positive/Neutral Scenario Posits An Upside
ProPhase Labs (NASDAQ:PRPH) versus Grifols (NASDAQ:GRFS) Head to Head Survey
Brandes Investment Partners, LP Significantly Reduces Vanguard Value ETF by 99.61%
Down 10.4% in 4 Weeks, Here's Why Grifols (GRFS) Looks Ripe for a Turnaround